Ocumension Therapeutics
EyePoint Pharmaceuticals, Inc. · Director
Ocumension Therapeutics serves as a Director at EyePoint Pharmaceuticals, Inc., a firm focused on advancing therapies for eye diseases. The latest disclosure, dated January 16, 2024, reveals substantial sale activity amounting to approximately $37.2 million. This transaction marks the sole disclosed move for Ocumension Therapeutics, underscoring a significant engagement with EyePoint Pharmaceuticals (EYPT) in the healthcare sector.
Latest Trades
| Company | Value | Action | Price | Last Price |
|---|---|---|---|---|
| $37M1.9M shares | SellJan 11, 2024 | $19.45 | $13.04 |